
What will define the winners in a crowded GLP-1 era?
HH Kim, CEO and President of MetaVia, asks what the next generation of GLP-1 drugs might look like. Over the past two decades, only a few biotech sectors have experienced a hype cycle as rapid and publicly frenzied as the obesity drug sector. In just over a year, GLP-1s… Read More



